• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Dr Robert Gabbay Discusses SGLT2 Inhibitor Uptake Among Cardiologists, Nephrologists

Video

As time goes on, we're finding out more and more benefits of sodium glucose co-transporter 2 (SGLT2) inhibitors, said Robert A. Gabbay, MD, PhD, the chief science and medical officer at the American Diabetes Association.

Transcript

In the past decade, we’ve seen the SGLT2 class burst on to the scene, first in type 2 diabetes, and now in heart failure and renal disease. Are you seeing more patients with type 2 diabetes being prescribed these therapies by a cardiologist or nephrologist?

SGLT2 medications have really been a game changer in the world of diabetes, and we're finding out more and more benefits. As you know, this started off as a story about cardiovascular disease, it's now extended to renal disease. One initiative that the American Diabetes Association is leading in collaboration with the American Heart Association, is a program called No Diabetes by Heart. That effort, that has been a 3-year activity by us, aimed at consumers in general, at people with diabetes and at providers and health systems, has been moving the needle. We've done some recent survey data across the country that indicates that, particularly to the target providers that we've been looking at, and that is cardiologists and nephrologists, are more confident and more knowledgeable about these medications, and now increasingly view this as their responsibility to prescribe these medications. So we are seeing progress, but we still have further to go.

Related Videos
Screenshot of Stephen Freedland, MD, during a video interview
Phaedra Corso, PhD, associate vice president for research at Indiana University
Julie Patterson, PharmD, PhD
William Padula, PhD, MSc, MS, assistant professor of pharmaceutical and health economics, University of California Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences
Dr Chris Pagnani
Screenshot of Angela Jia, MD, PhD, during a video interview
Nancy Dreyer, MPH, PhD, FISE, chief scientific advisor to Picnic Health
Screenshot of Alexander Kutikov, MD, during a video interview
Screenshot of Mary Dunn, MSN, NP-C, OCN, RN, during a video interview
Seth Berkowitz, MD, MPH, associate professor of medicine, University of North Carolina at Chapel Hill
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.